Abstract: This invention relates to the field of cancer therapy. More particularly, the invention relates to the treatment of mammary tumor, clinically manifest mammary tumor (breast cancer) and metastatic mammary tumor by administration of human Chorionic Gonadotropin (hCG). The treatment preferably comprises the administration of hCG in conjunction with an antiestrogen and/or a Type I Interferon.

Abstract: The present invention is directed to a method of treating estrogen responsive breast cancer in an individual comprising administering to an individual a therapeutically effective estradiol inhibiting amount of interferon gamma (IFN-?) and/for a tumor necrosis factor (TNF) antagonist and/or an interleukin-1 (IL-1) antagonists. The invention is based upon the surprising discovery that IFN-? and/or a tumor necrosis factor (TNF) antagonist and/or an interleukin-1 (IL-1) antagonists inhibit estradiol production in human adipocytes. This discovery is not only important because it allows for the treatment and/or prevention of estrogen dependent breast cancer using IFN-?, TNF antagonists or IL-1 antagonist each alone or in combination, but also because IFN-? and/or TNF antagonists and/or IL-1 antagonists can be used in conjunction with standard anti-estrogen therapy, e.g., tamoxifen and/or aromatase inhibitor, to result in lower estrogen levels than seen with standard anti-estrogen therapy alone.